BioCentury
ARTICLE | Clinical News

Brincidofovir: Phase III data

May 16, 2016 7:00 AM UTC

Next half, Chimerix plans to disclose final 36-week mortality data from AdVise. The company will not seek brincidofovir’s approval based on the AdVise data and instead intends to conduct a comparative...